TISIDB

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane; Peripheral membrane protein. Note=Thought to be anchored in the membrane through an interaction with SR-beta, which contains a bona fide transmembrane domain.
Domain	PF04086 Signal recognition particle PF00448 SRP54-type protein PF02881 SRP54-type protein
Function	Component of the SRP (signal recognition particle) receptor. Ensures, in conjunction with the signal recognition particle, the correct targeting of the nascent secretory proteins to the endoplasmic reticulum membrane system.

> Gene Ontology [ TOP ]
Biological Process	GO:0006612 protein targeting to membrane GO:0006613 cotranslational protein targeting to membrane GO:0006614 SRP-dependent cotranslational protein targeting to membrane GO:0006986 response to unfolded protein GO:0030968 endoplasmic reticulum unfolded protein response GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0036498 IRE1-mediated unfolded protein response GO:0045047 protein targeting to ER GO:0070972 protein localization to endoplasmic reticulum GO:0072599 establishment of protein localization to endoplasmic reticulum GO:0072657 protein localization to membrane GO:0090150 establishment of protein localization to membrane
Molecular Function	GO:0003924 GTPase activity GO:0005047 signal recognition particle binding GO:0005525 GTP binding GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding GO:0043021 ribonucleoprotein complex binding
Cellular Component	GO:0005785 signal recognition particle receptor complex GO:0005791 rough endoplasmic reticulum GO:0030867 rough endoplasmic reticulum membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03060 Protein export
Reactome	R-HSA-381070: IRE1alpha activates chaperones R-HSA-392499: Metabolism of proteins R-HSA-381119: Unfolded Protein Response (UPR) R-HSA-381038: XBP1(S) activates chaperone genes

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SRPR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SRPR in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.82	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SRPR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.044	0.859
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.195	0.944
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.074	0.97
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.329	0.259
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.052	0.982
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.681	0.822
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.026	0.951
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.159	0.937
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.145	0.949
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.164	0.932
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.45	0.875
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0	1

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SRPR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRPR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRPR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRPR. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRPR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SRPR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SRPR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SRPR
Name	signal recognition particle receptor (docking protein)
Aliases	SRP-alpha; Sralpha; signal recognition particle receptor ('docking protein'); DP-alpha; SR-alpha; docking pr ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SRPR collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SRPR